Drinking Intensity · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Frequency of drinking (no. binges/wk) at 12 months · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Adverse effects · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Quantity of drinking (g/week) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Frequency of drinking (no. binges/wk) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Treatment failure Need for additional treatment · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in treatment failure Need for additional treatment compared with SCS treatment (moderate certainty).
1 finding from 1 review
Relapse New acute exacerbation or COPD‐related admission · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in relapse New acute exacerbation or COPD‐related admission compared with SCS treatment (moderate certainty).
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in adverse drug effect—hyperglycaemia compared with SCS treatment (moderate certainty).
1 finding from 1 review
Adverse drug effects Gastrointestinal tract bleeding, symptomatic gastrointestinal reflux, symptoms of congestive heart failure or ischaemic heart disease, sleep disturbance, fractures, depression · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in adverse drug effects Gastrointestinal tract bleeding, symptomatic… compared with SCS treatment (low certainty).
1 finding from 1 review
All‐cause mortality · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in mortality compared with SCS treatment (moderate certainty).
1 finding from 1 review
Length of hospitalisation (days) · exacerbations of COPD
1 finding from 1 review
FEV1 · exacerbations of COPD
1 finding from 1 review
QoL · exacerbations of COPD
1 finding from 1 review
Stone clearance · adult patients presenting with symptoms of ureteral stone disease
Alpha‐blockers may leads to higher stone clearance compared with standard therapy (low certainty).
1 finding from 1 review
Pain episodes · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review
Dose of diclofenac (mg) · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review